Imunon, Inc. (IMNN): Nasdaq/NYSE listing notice — Imunon receives Nasdaq deficiency notice for bid price below $1.00 per share

Imunon, Inc.

Received Nasdaq deficiency letter on Dec. 26, 2023; bid price closed below $1.00 for 30 consecutive business days.
Given 180-day cure period until June 24, 2024; must have bid price >=$1.00 for 10 consecutive business days.
If not compliant by June 24, 2024, may be eligible for second 180-day compliance period subject to other listing standards.
Failure to cure could result in delisting; company may appeal any delisting determination.
No immediate effect on listing; shares continue trading on Nasdaq Capital Market under IMNN.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Imunon, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 26, 2023, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market, which continues to trade under the symbol “IMNN”. In accordance with Nasdaq Listi

View on SEC.gov

Browse all listing & compliance notices →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-046587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.